Suzhou Zelgen Biopharmaceuticals Co., Ltd. Stock: price and insider trades · China
泽璟制药
No insider purchase over the last 90 days. The latest, by JISHENG WU(吴济生), was filed 18 Jul 2022.
Suzhou Zelgen Biopharmaceuticals Co., Ltd.: what insiders have been doing
Suzhou Zelgen Biopharmaceuticals Co., Ltd. is a Health Care company. Its directors and officers file their transactions with SSE / SZSE (CSRC). In the past year (4 November 2025 to 4 November 2026), 1 filing came from 1 insider.
The flow runs one way only: 1 sale worth €3.5M, from 1 insider, and no purchase. The largest single trade was a sale of €3.5M by Zelin Sheng(盛泽林), published on 16 April 2026.
Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Compared with its exchange (517 companies, median 2 filings), a count of 1 filing is below the norm. Looking back to 2022, when coverage begins, insiders filed 31 purchases and 1 sale.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and UCB. Source: insider filings from SSE / SZSE (CSRC). Past trades are no guide to future returns.
Who traded when
BuySaleSince the insiders bought
- +42.7%Entry CN¥33.86 · Close at T+365 CN¥48.32
- +27.3%Entry CN¥36.32 · Close at T+365 CN¥46.22
- +111.2%Entry CN¥27.10 · Close at T+365 CN¥57.23
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 273,907 shares70.7% of flowA股XSHGSSE:273000000422970880
- 1,784 shares6.1% of flowA股XSHGSSE:173000005692962100Canonical exit: 16 Oct 2022 (T+90)
- 200 shares0.8% of flowA股XSHGSSE:173000005662820540Canonical exit: 5 Oct 2022 (T+90)
- 2,079 shares8.7% of flowA股XSHGSSE:173000005659772930Canonical exit: 4 Oct 2022 (T+90)
- 1,050 shares3.6% of flowA股XSHGSSE:173000005649137920Canonical exit: 29 Sept 2022 (T+90)
- 2,360 shares9.3% of flowA股XSHGSSE:173000005649150940Canonical exit: 29 Sept 2022 (T+90)
- 2,000 shares5.3% of flowA股XSHGSSE:173000005547914300Canonical exit: 22 Aug 2022 (T+90)
- 920 shares0.1% of flowA股XSHGSSE:173000005547914780Canonical exit: 22 Aug 2022 (T+90)
- 8,000 shares23.7% of flowA股XSHGSSE:173000005547913570Canonical exit: 22 Aug 2022 (T+90)
- 3,500 shares11.0% of flowA股XSHGSSE:173000005539713440Canonical exit: 17 Aug 2022 (T+90)
- 2,000 shares50.7% of flowA股XSHGSSE:173000005378610140Canonical exit: 20 Jun 2022 (T+90)
- 27,380 shares2.9% of flowA股XSHGSSE:173000005378757300Canonical exit: 20 Jun 2022 (T+90)
- 9,900 shares30.0% of flowA股XSHGSSE:173000005376467140Canonical exit: 19 Jun 2022 (T+90)
- 1,000 shares2.9% of flowA股XSHGSSE:173000005369557100Canonical exit: 15 Jun 2022 (T+90)
- 2,000 shares6.7% of flowA股XSHGSSE:173000005367543580Canonical exit: 14 Jun 2022 (T+90)
- 8,000 shares22.4% of flowA股XSHGSSE:173000005367280000Canonical exit: 14 Jun 2022 (T+90)
- 30,000 shares3.0% of flowA股XSHGSSE:173000005367546620Canonical exit: 14 Jun 2022 (T+90)
- 3,000 shares100.0% of flowA股XSHGSSE:173000005367279940Canonical exit: 14 Jun 2022 (T+90)
- 11,000 shares38.5% of flowA股XSHGSSE:173000005365277760Canonical exit: 13 Jun 2022 (T+90)
- 5,000 shares14.5% of flowA股XSHGSSE:173000005365093660Canonical exit: 13 Jun 2022 (T+90)
- 8,820 shares34.6% of flowA股XSHGSSE:173000005365279170Canonical exit: 13 Jun 2022 (T+90)
- 6,000 shares75.7% of flowA股XSHGSSE:173000005361025180Canonical exit: 12 Jun 2022 (T+90)
- 7,000 shares25.6% of flowA股XSHGSSE:173000005361184800Canonical exit: 12 Jun 2022 (T+90)
- 3,011 shares12.0% of flowA股XSHGSSE:173000005358936770Canonical exit: 9 Jun 2022 (T+90)
- 2,000 shares49.3% of flowA股XSHGSSE:173000005358674400Canonical exit: 9 Jun 2022 (T+90)
25 of 32 declarations
About Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Zai Lab is a company focused on developing innovative medicines, particularly in oncology. It is listed on the Shanghai Stock Exchange.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
